SAB Biotherapeutics (SABSW) Enterprise Value (2020 - 2025)
SAB Biotherapeutics' Enterprise Value history spans 6 years, with the latest figure at -$96.6 million for Q4 2025.
- For Q4 2025, Enterprise Value fell 365.27% year-over-year to -$96.6 million; the TTM value through Dec 2025 reached -$96.6 million, down 365.27%, while the annual FY2025 figure was -$96.6 million, 365.27% down from the prior year.
- Enterprise Value reached -$96.6 million in Q4 2025 per SABSW's latest filing, up from -$110.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$2.4 million in Q3 2023 to a low of -$110.9 million in Q3 2025.
- Average Enterprise Value over 5 years is -$29.1 million, with a median of -$18.4 million recorded in 2021.
- Peak YoY movement for Enterprise Value: crashed 1154.58% in 2024, then surged 84.69% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$39.5 million in 2021, then skyrocketed by 61.95% to -$15.0 million in 2022, then tumbled by 275.93% to -$56.6 million in 2023, then skyrocketed by 63.3% to -$20.8 million in 2024, then crashed by 365.27% to -$96.6 million in 2025.
- Per Business Quant, the three most recent readings for SABSW's Enterprise Value are -$96.6 million (Q4 2025), -$110.9 million (Q3 2025), and -$5.7 million (Q2 2025).